Table 2.
Studies recruiting ≥100 HCV-positive diabetic patients and reporting significant glycometabolic amelioration after successful therapy with DAAs.
| Author, Year, (Ref.) | Type of Study | Design | N. | Mean FPG Change (p) | Mean HbA1c Level Change (p) | Follow-Up |
|---|---|---|---|---|---|---|
| Hum et al., 2017 [178] | Observational | Retrospective | 2180 | Not determined | −0.37% (0.03) * | 48 weeks |
| Dawood et al., 2017 [179] | Clinical trial | Open label | 378 | −23.4 mg/dL (N.A) | −0.45% (N.A.) | 12 weeks |
| Ciancio et al., 2018 [180] | Observational | Prospective | 101 | −18.0 mg/dL (0.002) | −0.5% (<0.001) | 12 weeks |
| Gilad et al., 2019 [181] | Observational | Retrospective | 122 | Not determined | −0.6% (0.001) | 1.5 years |
| Li et al., 2019 [182] | Observational | Retrospective/Prospective | 192 | Not determined | −2.3 (<0.001) | 24 weeks |
| Boraie et al., 2019 [183] | Observational | Prospective | 116 | −8.4 mg/dL (0.01) | 0.9% (0.008) | 12 weeks |
| Andres et al., 2020 [184] | Observational | Retrospective | 310 | Not determined. | −0.27% (0.014) | 1.6 years |
| Wong, 2020 [185] | Observational | Retrospective | 937 | Not determined | −0.39% (<0.0001) | 12 months |
| Zied, 2020 [186] | Observational | Prospective | 100 | −107 mg/dL (0.005) | −0.41% (0.003) | 12 w |
| Ciancio, 2021 [187] | Observational | Prospective | 141 | −15 mg/dL (0.001) | −0.7% (0.003) | 44.5 months |
DAAs = Direct Acting Antiviral Agents; HCV = Hepatitis C Virus; ref. = reference; N. = Number; HbA1c = Haemoglobin A1c; N.A. = not available; * = −0.13%, p = 0.01 when adjusted by multiple regression analysis.